Belinostat (PXD101)
>98%
- Product Code: 103546
CAS:
414864-00-9
| Molecular Weight: | 318.35 g./mol | Molecular Formula: | C₁₅H₁₄N₂O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Belinostat is primarily used in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), a rare and aggressive type of non-Hodgkin lymphoma. It functions as a histone deacetylase (HDAC) inhibitor, which helps to regulate gene expression and induce apoptosis in cancer cells. The drug is administered intravenously and is often considered when other treatment options have failed. Its ability to target epigenetic modifications makes it a valuable option in oncology, particularly for patients with limited therapeutic alternatives. Additionally, ongoing research is exploring its potential in treating other types of cancers, such as ovarian cancer and soft tissue sarcoma, to expand its clinical applications.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Off-White Powder Or Crystals |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | ฿10,530.00 |
+
-
|
Belinostat (PXD101)
Belinostat is primarily used in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), a rare and aggressive type of non-Hodgkin lymphoma. It functions as a histone deacetylase (HDAC) inhibitor, which helps to regulate gene expression and induce apoptosis in cancer cells. The drug is administered intravenously and is often considered when other treatment options have failed. Its ability to target epigenetic modifications makes it a valuable option in oncology, particularly for patients with limited therapeutic alternatives. Additionally, ongoing research is exploring its potential in treating other types of cancers, such as ovarian cancer and soft tissue sarcoma, to expand its clinical applications.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :